Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation
Hans TH Tu, Bruce CV Campbell, Soren Christensen, Patricia M Desmond, Deidre A De Silva, Mark W Parsons, Leonid Churilov, Maarten G Lansberg, Michael Mlynash, Jean-Marc Olivot, Matus Straka, Roland Bammer, Gregory W Albers, Geoffrey A Donnan, Stephen M Davis
International Journal of Stroke | SAGE PUBLICATIONS LTD | Published : 2015
Awarded by National Institutes of Health (NIH)
Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
The EPITHET study was supported by the National Health and Medical Research Council of Australia (NHMRC), National Stroke Foundation (NSF), and National Heart Foundation of Australia (NHF). The DEFUSE study was funded by National Institutes of Health (NIH) Grants RO1 NS39325, Principal Investigator, Gregory W. Albers; K24 NS044848, Principal Investigator, Gregory W. Albers; K23 NS051372, Principal Investigator, Maarten G. Lansberg; and the RAPID software development was supported by R01 EB002711, Principal Investigator, Roland Bammer. Hans Tu is supported by the Royal Melbourne Hospital Neurosciences Foundation. Tissue plasminogen activator was supplied at no charge by Boehringer Ingelheim (Australian, New Zealand, and European sites) and Genentech (US and Canadian sites). Neither Boehringer Ingelheim, Genentech, NIH, NHMRC, NSF, NHF, nor the Royal Melbourne Hospital Neurosciences Foundation played a role in the design and the conduct of the studies; collection, management, analysis, and interpretation of the data; or preparation or approval of the manuscript.